Based on preliminary evidence, SGLT2 inhibitors represent a promising adjunct in the management of AS by targeting key elements of myocardial pathobiology—fibrosis, inflammation, oxidative stress, and metabolic dysfunction. Here, SLC5A2 is linked to aortic valve stenosis.